Table 2

Parameters studied in relation to 5-year survival in the 101 STS

ParameterTotal no.5-year follow-up
DOD
NED
Total (%)(MFH, LPS)Total (MFH, LPS)
Clinical
    SexFemale5426 (48)(13, 5)28 (17, 3)
Male4722 (48)(17, 2)24 (17, 6)
    DepthS.c.225 (23)(2, 0)17 (13, 2)
Extracompartmental2615 (60)(10, 2)10 (6, 1)
I.m.4521 (47)(12, 4)24 (14,6)
    Size (cm)≤6326 (19)(2, 2)26 (20, 2)
7-112310 (43)(9, 1)13 (8, 2)
>113323 (70)(15, 3)9 (5, 3)
    Surgical marginWide4420 (47)(10, 3)23 (15, 5)
Marginal319 (29)(5, 2)22 (14, 4)
Intralesional1711 (65)(8, 1)6 (4, 0)
Histopathological
    Malignancy gradeGrade 33816 (43)(8, 3)21 (13, 4)
Grade 46332 (51)(22, 4)31 (21, 5)
    NecrosisYes7741 (54)(26, 7)35 (24, 5)
No247 (29)(4, 0)17 (10, 4)
    Mitosis0-2 per HPF216 (30)(1, 2)14 (8, 3)
3-10 per HPF3014 (47)(12, 1)16 (10, 4)
>10 per HPF4827 (56)(16, 4)21 (16, 2)
    Growth patternPushing72 (29)(1, 0)5 (2, 2)
Infiltrative8944 (50)(27, 7)44 (31, 5)
    Vascular invasionYes115 (45)(3, 0)6 (3, 0)
No8442 (51)(26, 7)41 (28, 7)
Immunohistochemical
    Ki-67≤10% positive cells103 (30)(1, 1)7 (2, 3)
>10% positive cells6935 (51)(22, 5)33 (23, 4)
    p53≤40% positive cells6833 (49)(18, 6)35 (23, 6)
>40% positive cells198 (44)(6, 1)10 (7, 3)
    Vessel density≤30 per HPF6736 (53)(19, 7)31 (19, 6)
>30 per HPF238 (35)(7, 0)15 (10, 2)
    Bcl-2≤30% positive cells8438 (46)(24, 6)45 (28, 9)
>30% positive cells85 (62)(2, 1)3 (2, 0)
    p27≤30% positive cells4520 (44)(15, 1)25 (16, 4)
>30% positive cells4523 (52)(11, 6)21 (13, 5)
    IGF-1R≤50% positive cells6936 (52)(21, 7)33 (21, 7)
>50% positive cells185 (29)(4, 0)12 (7, 1)
  • NOTE: (x, x), figures in parenthesis represent MFH and LPS.

  • Abbreviations: NED, no evidence of disease at the end of follow-up; DOD, death from or with disease; LPS, liposarcoma; HPF, high power field.